ArticleFrontiers in bioinformatics2026
Immunoinformatic-guided design of a polo-like kinase 1 (PLK1)-targeted multi-epitope vaccine with preliminary
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polo-like kinase 1 (PLK1) is a well-established oncogenic protein, as indicated by elevated levels of protein expression and function in a variety of tumor malignancies, and thus helps in metastasis of the disease. To target the PLK1, the study designed a cancer antigen that is capable of activating enhanced immune signaling pathways using an immunoinformatic approach. Methodology: To achieve the study's objective initially, the potential B- and T-cell epitopes were screened through IEDB resources. By analyzing immunological profiles, the highly antigenic, non-toxic and non-allergenic epitopes were screened and further utilized for vaccine design. Using appropriate linkers and adapters, the multi-epitope vaccine was constructed, and subsequent structural modelling and validation were analyzed. Following that, the immunogenic potential was analyzed through molecular docking, molecular dynamic simulations, and immune simulations. Results: Four highly antigenic B-cell, five CTL, and five HTL epitopes along with linkers and 50s ribosomal adjuvants were utilized for vaccine construction. The subsequent physicochemical characterization and structural validation revealed that the PLK1 vaccine is considered highly stable. The molecular interactions with innate receptors revealed that the PLK1 vaccine had high binding affinity with the TLR4 receptor (-402.83 kcal/mol) compared to TLR2. The investigations under physiological conditions exhibited that the PLK1 vaccine with TLR complexes maintained structurally stable conformations. The elevated level of IFN-gamma and IL-2 productions was observed in the immune simulation analysis. The final recombinant length of the optimized gene expression was observed to be 6,488 bps. A decrease in PLK1 transcript levels was observed in the SKBR3 cells after treatment with specific CTL epitopes. Discussion: The enhanced immune profiles of the constructed PLK1 demonstrated a favourable predicted interaction with TLR4, suggesting a potential receptor recognition that may associated with Th1-mediated immune responses. Conclusion: Overall, the PLK1 cancer antigen may act as a promising candidate in the context of cancer immunotherapy. Further, experimental validation in proper animal models is required to validate its immunogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.